Targeting BRAF pathway in low-grade serous ovarian cancer

• Published in: Journal of gynecologic oncology 2024, 35(4), , pp.1-15
• Main Authors: Perrone, Chiara, Angioli, Roberto, Luvero, Daniela, Giannini, Andrea, Di Donato, Violante, Cuccu, Ilaria, Muzii, Ludovico, Raspagliesi, Francesco, Bogani, Giorgio
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - pathology; Female; Humans; Imidazoles - pharmacology; Imidazoles - therapeutic use; MAP Kinase Signaling System - drug effects; Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors; Molecular Targeted Therapy; Neoplasm Grading; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Oximes; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; Proto-Oncogene Proteins B-raf - genetics; Review; Sulfonamides - therapeutic use; 산부인과학
• ISSN: 2005-0380; 2005-0399; 2005-0399
• DOI: 10.3802/jgo.2024.35.e104

Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities including ovarian carcinomas. In the recent years, several inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Low grade serous ovarian carcinoma, is a rare gynecological tumor which shows favorable overall survival, compared to the general ovarian cancer population, but worrying resistance to conventional chemotherapies. The clinical behavior of low grade serous ovarian carcinoma reflects the different gene profile compared to high-grade serous carcinoma: / mutations. BRAF inhibitors as single agents were approved for the treatment of mutated tumors. Nevertheless, many patients face progressive disease. The understanding of the mechanisms of resistance to BRAF inhibitors therapy and preclinical studies showing that BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors combined therapy delays the onset of resistance compared to BRAF inhibitor single agent, led to the clinical investigation of combined therapy. The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors on ovarian carcinomas, in particularly focusing on low grade serous ovarian carcinoma.